Third Death In Audentes’ XLMTM Gene Therapy Trial
But Companies Remain 'Committed'
Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.
You may also be interested in...
Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.
Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.